Dan  Goldstein net worth and biography

Dan Goldstein Biography and Net Worth

Dan Goldstein works as a Controller at Haemonetics, which is a Manufacturing company with an estimated 2,821 employees; and founded in 1971. They are part of the Accounting team within the Finance Department and their management level is Non-Manager. Dan graduated from University Of Michigan in 1998 and is currently based in Boston, United States.

What is Dan Goldstein's net worth?

The estimated net worth of Dan Goldstein is at least $374,259.52 as of June 13th, 2022. Mr. Goldstein owns 4,447 shares of Haemonetics stock worth more than $374,260 as of March 27th. This net worth evaluation does not reflect any other assets that Mr. Goldstein may own. Learn More about Dan Goldstein's net worth.

How do I contact Dan Goldstein?

The corporate mailing address for Mr. Goldstein and other Haemonetics executives is 125 Summer Street, Boston MA, 02110. Haemonetics can also be reached via phone at (781) 848-7100 and via email at [email protected]. Learn More on Dan Goldstein's contact information.

Has Dan Goldstein been buying or selling shares of Haemonetics?

Dan Goldstein has not been actively trading shares of Haemonetics in the last ninety days. Most recently, Dan Goldstein sold 42 shares of the business's stock in a transaction on Monday, June 13th. The shares were sold at an average price of $62.60, for a transaction totalling $2,629.20. Following the completion of the sale, the vice president now directly owns 4,447 shares of the company's stock, valued at $278,382.20. Learn More on Dan Goldstein's trading history.

Who are Haemonetics' active insiders?

Haemonetics' insider roster includes Michelle Basil (EVP), William Burke (CFO), Dan Goldstein (VP), Mark Kroll (Director), Anila Lingamneni (EVP), Josep Llorens (EVP), Richard Meelia (Director), Laurie Miller (SVP), Jacqueline Scanlan (SVP), Christopher Simon (CEO), and Stewart Strong (Insider). Learn More on Haemonetics' active insiders.

Are insiders buying or selling shares of Haemonetics?

During the last twelve months, insiders at the medical instruments supplier sold shares 4 times. They sold a total of 9,765 shares worth more than $863,630.52. The most recent insider tranaction occured on September, 12th when insider Stewart W Strong sold 228 shares worth more than $20,668.20. Insiders at Haemonetics own 1.8% of the company. Learn More about insider trades at Haemonetics.

Information on this page was last updated on 9/12/2023.

Dan Goldstein Insider Trading History at Haemonetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/13/2022Sell42$62.60$2,629.204,447View SEC Filing Icon  
6/2/2022Sell249$62.69$15,609.814,489View SEC Filing Icon  
5/16/2022Sell50$56.10$2,805.004,004View SEC Filing Icon  
6/14/2021Sell39$59.87$2,334.93View SEC Filing Icon  
6/7/2021Sell81$55.09$4,462.29View SEC Filing Icon  
5/19/2021Sell42$55.19$2,317.98View SEC Filing Icon  
5/17/2021Sell42$55.97$2,350.74View SEC Filing Icon  
2/4/2021Sell2,671$135.86$362,882.06View SEC Filing Icon  
10/26/2020Sell100$106.00$10,600.00View SEC Filing Icon  
6/16/2020Sell4,456$90.25$402,154.00View SEC Filing Icon  
6/12/2020Sell42$82.29$3,456.18View SEC Filing Icon  
6/9/2020Sell1,376$96.23$132,412.48View SEC Filing Icon  
5/18/2020Sell101$101.72$10,273.72View SEC Filing Icon  
5/15/2020Sell42$100.44$4,218.48View SEC Filing Icon  
4/8/2020Sell399$97.12$38,750.88View SEC Filing Icon  
4/6/2020Sell2,607$101.62$264,923.34View SEC Filing Icon  
10/28/2019Sell100$120.33$12,033.00View SEC Filing Icon  
10/25/2019Sell1,456$120.32$175,185.92View SEC Filing Icon  
8/9/2019Sell475$133.23$63,284.25View SEC Filing Icon  
6/12/2019Sell39$109.37$4,265.43View SEC Filing Icon  
6/10/2019Sell192$104.38$20,040.96View SEC Filing Icon  
6/6/2019Sell1,107$103.25$114,297.75View SEC Filing Icon  
4/9/2019Sell3,206$88.90$285,013.40View SEC Filing Icon  
12/10/2018Sell1,693$102.91$174,226.63View SEC Filing Icon  
10/26/2018Sell102$101.69$10,372.38View SEC Filing Icon  
6/7/2018Sell3,794$95.09$360,771.46View SEC Filing Icon  
4/6/2018Sell518$54.65$28,308.704,002View SEC Filing Icon  
11/13/2017Sell4,691$54.93$257,676.633,747View SEC Filing Icon  
See Full Table

Dan Goldstein Buying and Selling Activity at Haemonetics

This chart shows Dan Goldstein's buying and selling at Haemonetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Haemonetics Company Overview

Haemonetics logo
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $84.16
Low: $82.30
High: $84.16

50 Day Range

MA: $77.18
Low: $71.25
High: $84.61

2 Week Range

Now: $84.16
Low: $70.74
High: $95.26

Volume

298,229 shs

Average Volume

468,810 shs

Market Capitalization

$4.27 billion

P/E Ratio

34.21

Dividend Yield

N/A

Beta

0.34